NasdaqGS:COGTBiotechs
Cogent Biosciences Balances Bezuclastinib Phase 3 Progress With Dilution Risk
Cogent Biosciences (NasdaqGS:COGT) has advanced its lead therapy bezuclastinib into a Phase 3 trial for systemic mastocytosis.
The company has also filed a significant shelf registration that could be used to raise capital in the future.
These updates highlight progress in Cogent Biosciences' clinical pipeline alongside preparations for potential funding needs.
Cogent Biosciences enters this news cycle with its shares at $39.18 and very large 1 year returns, reflecting strong recent...